Evidence map›Paper›PMID 20334680›Full record

Trial reportBMC psychiatry2010

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.

Erik Johnsen, Rune A Kroken, Tore Wentzel-Larsen, Hugo A Jørgensen

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00932529 (Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00932529 phase4completednot on this map

Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.

TypeinterventionalSponsorUniversity of BergenRan2003 to 2010Enrolled226ConditionsPsychotic DisordersArmsOlanzapine, Quetiapine, Risperidone, Ziprasidone
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Erik JohnsenDivision of Psychiatry, H aukeland University Hospital, Sandviken, Pb 23, N-5812 Bergen, Norway. erij@ihelse.net
Rune A Kroken
Tore Wentzel-Larsen
Hugo A Jørgensen
Haukeland University Hospital · NOSandvik (Norway) · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNo clear recommendations exist regarding which antipsychotic drug should be prescribed first for a patient suffering from psychosis. The primary aims of this naturalistic study were to assess the head-to-head effectiveness of first-line second-generation antipsychotics with regards to time until drug discontinuation, duration of index admission, time until readmission, change of psychopathology scores and tolerability outcomes.

methodsPatients >or= 18 years of age admitted to the emergency ward for symptoms of psychosis were consecutively randomized to risperidone (n = 53), olanzapine (n = 52), quetiapine (n = 50), or ziprasidone (n = 58), and followed for up to 2 years.

resultsA total of 213 patients were included, of which 68% were males. The sample represented a diverse population suffering from psychosis. At admittance the mean Positive and Negative Syndrome Scale (PANSS) total score was 74 points and 44% were antipsychotic drug naïve. The primary intention-to-treat analyses revealed no substantial differences between the drugs regarding the times until discontinuation of initial drug, until discharge from index admission, or until readmission. Quetiapine was superior to risperidone and olanzapine in reducing the PANSS total score and the positive subscore. Quetiapine was superior to the other drugs in decreasing the PANSS general psychopathology subscore; in decreasing the Clinical Global Impression - Severity of Illness scale score (CGI-S); and in increasing the Global Assessment of Functioning - Split version, Functions scale score (GAF-F). Ziprasidone was superior to risperidone in decreasing the PANSS positive symptoms subscore and the CGI-S score, and in increasing the GAF-F score. The drugs performed equally with regards to most tolerability outcomes except a higher increase of hip-circumference per day for olanzapine compared to risperidone, and more galactorrhoea for risperidone compared to the other groups.

conclusionsQuetiapine appears to be a good starting drug candidate in this sample of patients admitted to hospital for symptoms of psychosis.

trial registrationClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/: NCT00932529.

Indexed as

AdultAntipsychotic AgentsBenzodiazepinesDibenzothiazepinesDrug Administration ScheduleDyskinesia, Drug-InducedFemaleGalactorrheaHospitalizationHumansLength of StayMaleOlanzapinePatient ReadmissionPiperazinesPsychiatric Status Rating ScalesAntipsychotic AgentsBenzodiazepinesDibenzothiazepinesOlanzapinePiperazinesQuetiapine FumarateRisperidoneThiazolesziprasidone

Identifiers

PMID20334680
PMCPMC2851682
OpenAlexW2137232294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.